schliessen

Filtern

 

Bibliotheken

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

Neoadjuvant chemotherapy for breast cancer allows individual tumor response to be assessed depending on molecular subtype, and to judge the impact of response to therapy on recurrence-free survival (RFS). The multicenter I-SPY 1 TRIAL evaluated patients with ≥3 cm tumors by using early imaging and m... Full description

Journal Title: Breast Cancer Research and Treatment 2012, Vol.132(3), pp.1049-1062
Main Author: Esserman, Laura
Other Authors: Berry, Donald , Cheang, Maggie , Yau, Christina , Perou, Charles , Carey, Lisa , DeMichele, Angela , Gray, Joe , Conway-Dorsey, Kathleen , Lenburg, Marc , Buxton, Meredith , Davis, Sarah , Veer, Laura , Hudis, Clifford , Chin, Koei , Wolf, Denise , Krontiras, Helen , Montgomery, Leslie , Tripathy, Debu , Lehman, Constance , Liu, Minetta , Olopade, Olufunmilayo , Rugo, Hope , Carpenter, John , Livasy, Chad , Dressler, Lynn , Chhieng, David , Singh, Baljit , Mies, Carolyn , Rabban, Joseph , Chen, Yunni-Yi , Giri, Dilip , Au, Alfred , Hylton, Nola
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0167-6806 ; E-ISSN: 1573-7217 ; DOI: 10.1007/s10549-011-1895-2
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: springer_jour10.1007/s10549-011-1895-2
title: Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
format: Article
creator:
  • Esserman, Laura
  • Berry, Donald
  • Cheang, Maggie
  • Yau, Christina
  • Perou, Charles
  • Carey, Lisa
  • DeMichele, Angela
  • Gray, Joe
  • Conway-Dorsey, Kathleen
  • Lenburg, Marc
  • Buxton, Meredith
  • Davis, Sarah
  • Veer, Laura
  • Hudis, Clifford
  • Chin, Koei
  • Wolf, Denise
  • Krontiras, Helen
  • Montgomery, Leslie
  • Tripathy, Debu
  • Lehman, Constance
  • Liu, Minetta
  • Olopade, Olufunmilayo
  • Rugo, Hope
  • Carpenter, John
  • Livasy, Chad
  • Dressler, Lynn
  • Chhieng, David
  • Singh, Baljit
  • Mies, Carolyn
  • Rabban, Joseph
  • Chen, Yunni-Yi
  • Giri, Dilip
  • Au, Alfred
  • Hylton, Nola
subjects:
  • Breast cancer
  • Neoadjuvant chemotherapy
  • Molecular biomarkers
  • Pathologic complete response
ispartof: Breast Cancer Research and Treatment, 2012, Vol.132(3), pp.1049-1062
description: Neoadjuvant chemotherapy for breast cancer allows individual tumor response to be assessed depending on molecular subtype, and to judge the impact of response to therapy on recurrence-free survival (RFS). The multicenter I-SPY 1 TRIAL evaluated patients with ≥3 cm tumors by using early imaging and molecular signatures, with outcomes of pathologic complete response (pCR) and RFS. The current analysis was performed using data from patients who had molecular profiles and did not receive trastuzumab. The various molecular classifiers tested were highly correlated. Categorization of breast cancer by molecular signatures enhanced the ability of pCR to predict improvement in RFS compared to the population as a whole. In multivariate analysis, the molecular signatures that added to the ability of HR and HER2 receptors, clinical stage, and pCR in predicting RFS included 70-gene signature, wound healing signature, p53 mutation signature, and PAM50 risk of recurrence. The low risk signatures were associated with significantly better prognosis, and also identified additional patients with a good prognosis within the no pCR group, primarily in the hormone receptor positive, HER-2 negative subgroup. The I-SPY 1 population is enriched for tumors with a poor prognosis but is still heterogeneous in terms of rates of pCR and RFS. The ability of pCR to predict RFS is better by subset than it is for the whole group. Molecular markers improve prediction of RFS by identifying additional patients with excellent prognosis within the no pCR group.
language: eng
source:
identifier: ISSN: 0167-6806 ; E-ISSN: 1573-7217 ; DOI: 10.1007/s10549-011-1895-2
fulltext: fulltext_linktorsrc
issn:
  • 1573-7217
  • 15737217
  • 0167-6806
  • 01676806
url: Link


@attributes
ID415140945
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10.1007/s10549-011-1895-2
sourceidspringer_jour
recordidTN_springer_jour10.1007/s10549-011-1895-2
sourcesystemPC
pqid1013462362
galeid356581180
display
typearticle
titleChemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
creatorEsserman, Laura ; Berry, Donald ; Cheang, Maggie ; Yau, Christina ; Perou, Charles ; Carey, Lisa ; DeMichele, Angela ; Gray, Joe ; Conway-Dorsey, Kathleen ; Lenburg, Marc ; Buxton, Meredith ; Davis, Sarah ; Veer, Laura ; Hudis, Clifford ; Chin, Koei ; Wolf, Denise ; Krontiras, Helen ; Montgomery, Leslie ; Tripathy, Debu ; Lehman, Constance ; Liu, Minetta ; Olopade, Olufunmilayo ; Rugo, Hope ; Carpenter, John ; Livasy, Chad ; Dressler, Lynn ; Chhieng, David ; Singh, Baljit ; Mies, Carolyn ; Rabban, Joseph ; Chen, Yunni-Yi ; Giri, Dilip ; Au, Alfred ; Hylton, Nola
ispartofBreast Cancer Research and Treatment, 2012, Vol.132(3), pp.1049-1062
identifier
subjectBreast cancer ; Neoadjuvant chemotherapy ; Molecular biomarkers ; Pathologic complete response
descriptionNeoadjuvant chemotherapy for breast cancer allows individual tumor response to be assessed depending on molecular subtype, and to judge the impact of response to therapy on recurrence-free survival (RFS). The multicenter I-SPY 1 TRIAL evaluated patients with ≥3 cm tumors by using early imaging and molecular signatures, with outcomes of pathologic complete response (pCR) and RFS. The current analysis was performed using data from patients who had molecular profiles and did not receive trastuzumab. The various molecular classifiers tested were highly correlated. Categorization of breast cancer by molecular signatures enhanced the ability of pCR to predict improvement in RFS compared to the population as a whole. In multivariate analysis, the molecular signatures that added to the ability of HR and HER2 receptors, clinical stage, and pCR in predicting RFS included 70-gene signature, wound healing signature, p53 mutation signature, and PAM50 risk of recurrence. The low risk signatures were associated with significantly better prognosis, and also identified additional patients with a good prognosis within the no pCR group, primarily in the hormone receptor positive, HER-2 negative subgroup. The I-SPY 1 population is enriched for tumors with a poor prognosis but is still heterogeneous in terms of rates of pCR and RFS. The ability of pCR to predict RFS is better by subset than it is for the whole group. Molecular markers improve prediction of RFS by identifying additional patients with excellent prognosis within the no pCR group.
languageeng
source
version7
oafree_for_read
lds50peer_reviewed
links
openurl$$Topenurl_article
linktorsrc$$Uhttp://dx.doi.org/10.1007/s10549-011-1895-2$$EView_full_text_in_Springer
openurlfulltext$$Topenurlfull_article
search
creatorcontrib
0Esserman, Laura, J.
1Berry, Donald, A.
2Cheang, Maggie, C.
3Yau, Christina, M.
4Perou, Charles, W.
5Carey, Lisa, E.
6DeMichele, Angela, B.
7Gray, Joe, E.
8Conway-Dorsey, Kathleen, J.
9Lenburg, Marc, C.
10Buxton, Meredith, I.
11Davis, Sarah, S.
12Veer, Laura, T.
13Hudis, Clifford, T.
14Chin, Koei, T.
15Wolf, Denise, T.
16Krontiras, Helen, T.
17Montgomery, Leslie, T.
18Tripathy, Debu, T.
19Lehman, Constance, T.
20Liu, Minetta, T.
21Olopade, Olufunmilayo, T.
22Rugo, Hope, T.
23Carpenter, John, T.
24Livasy, Chad, T.
25Dressler, Lynn, T.
26Chhieng, David, T.
27Singh, Baljit, T.
28Mies, Carolyn, T.
29Rabban, Joseph, T.
30Chen, Yunni-Yi, T.
31Giri, Dilip, T.
32Au, Alfred, T.
33Hylton, Nola, T.
titleChemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
descriptionNeoadjuvant chemotherapy for breast cancer allows individual tumor response to be assessed depending on molecular subtype, and to judge the impact of response to therapy on recurrence-free survival (RFS). The multicenter I-SPY 1 TRIAL evaluated patients with ≥3 cm tumors by using early imaging and molecular signatures, with outcomes of pathologic complete response (pCR) and RFS. The current analysis was performed using data from patients who had molecular profiles and did not receive trastuzumab. The various molecular classifiers tested were highly correlated. Categorization of breast cancer by molecular signatures enhanced the ability of pCR to predict improvement in RFS compared to the population as a whole. In multivariate analysis, the molecular signatures that added to the ability of HR and HER2 receptors, clinical stage, and pCR in predicting RFS included 70-gene signature, wound healing signature, p53 mutation signature, and PAM50 risk of recurrence. The low risk signatures were associated with significantly better prognosis, and also identified additional patients with a good prognosis within the no pCR group, primarily in the hormone receptor positive, HER-2 negative subgroup. The I-SPY 1 population is enriched for tumors with a poor prognosis but is still heterogeneous in terms of rates of pCR and RFS. The ability of pCR to predict RFS is better by subset than it is for the whole group. Molecular markers improve prediction of RFS by identifying additional patients with excellent prognosis within the no pCR group.
subject
0Breast cancer
1Neoadjuvant chemotherapy
2Molecular biomarkers
3Pathologic complete response
general
010.1007/s10549-011-1895-2
1English
2Springer Science & Business Media B.V.
3SpringerLink Open Access
sourceidspringer_jour
recordidspringer_jour10.1007/s10549-011-1895-2
issn
01573-7217
115737217
20167-6806
301676806
rsrctypearticle
creationdate2012
addtitle
0Breast Cancer Research and Treatment
1Breast Cancer Res Treat
searchscopespringer_free
scopespringer_free
lsr30VSR-Enriched:[galeid, pages, pqid]
sort
titleChemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
authorEsserman, Laura ; Berry, Donald ; Cheang, Maggie ; Yau, Christina ; Perou, Charles ; Carey, Lisa ; DeMichele, Angela ; Gray, Joe ; Conway-Dorsey, Kathleen ; Lenburg, Marc ; Buxton, Meredith ; Davis, Sarah ; Veer, Laura ; Hudis, Clifford ; Chin, Koei ; Wolf, Denise ; Krontiras, Helen ; Montgomery, Leslie ; Tripathy, Debu ; Lehman, Constance ; Liu, Minetta ; Olopade, Olufunmilayo ; Rugo, Hope ; Carpenter, John ; Livasy, Chad ; Dressler, Lynn ; Chhieng, David ; Singh, Baljit ; Mies, Carolyn ; Rabban, Joseph ; Chen, Yunni-Yi ; Giri, Dilip ; Au, Alfred ; Hylton, Nola
creationdate20120400
facets
frbrgroupid8486652570930400566
frbrtype5
languageeng
creationdate2012
topic
0Breast Cancer
1Neoadjuvant Chemotherapy
2Molecular Biomarkers
3Pathologic Complete Response
collectionSpringerLink Open Access
prefilterarticles
rsrctypearticles
creatorcontrib
0Esserman, Laura
1Berry, Donald
2Cheang, Maggie
3Yau, Christina
4Perou, Charles
5Carey, Lisa
6DeMichele, Angela
7Gray, Joe
8Conway-Dorsey, Kathleen
9Lenburg, Marc
10Buxton, Meredith
11Davis, Sarah
12Veer, Laura
13Hudis, Clifford
14Chin, Koei
15Wolf, Denise
16Krontiras, Helen
17Montgomery, Leslie
18Tripathy, Debu
19Lehman, Constance
20Liu, Minetta
21Olopade, Olufunmilayo
22Rugo, Hope
23Carpenter, John
24Livasy, Chad
25Dressler, Lynn
26Chhieng, David
27Singh, Baljit
28Mies, Carolyn
29Rabban, Joseph
30Chen, Yunni-Yi
31Giri, Dilip
32Au, Alfred
33Hylton, Nola
jtitleBreast Cancer Research And Treatment
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext_linktorsrc
addata
aulast
0Esserman
1Berry
2Cheang
3Yau
4Perou
5Carey
6DeMichele
7Gray
8Conway-Dorsey
9Lenburg
10Buxton
11Davis
12Veer
13Hudis
14Chin
15Wolf
16Krontiras
17Montgomery
18Tripathy
19Lehman
20Liu
21Olopade
22Rugo
23Carpenter
24Livasy
25Dressler
26Chhieng
27Singh
28Mies
29Rabban
30Chen
31Giri
32Au
33Hylton
aufirst
0Laura
1J.
2Donald
3A.
4Maggie
5C.
6U.
7Christina
8Charles
9M.
10Lisa
11Angela
12Joe
13W.
14Kathleen
15Marc
16E.
17Meredith
18B.
19Sarah
20Clifford
21Koei
22Denise
23Helen
24Leslie
25Debu
26Constance
27Minetta
28Olufunmilayo
29I.
30Hope
31S.
32John
33T.
34Chad
35Lynn
36David
37Baljit
38Carolyn
39Joseph
40Yunni-Yi
41Dilip
42Alfred
43Nola
au
0Esserman, Laura
1Berry, Donald
2Cheang, Maggie
3Yau, Christina
4Perou, Charles
5Carey, Lisa
6DeMichele, Angela
7Gray, Joe
8Conway-Dorsey, Kathleen
9Lenburg, Marc
10Buxton, Meredith
11Davis, Sarah
12Veer, Laura
13Hudis, Clifford
14Chin, Koei
15Wolf, Denise
16Krontiras, Helen
17Montgomery, Leslie
18Tripathy, Debu
19Lehman, Constance
20Liu, Minetta
21Olopade, Olufunmilayo
22Rugo, Hope
23Carpenter, John
24Livasy, Chad
25Dressler, Lynn
26Chhieng, David
27Singh, Baljit
28Mies, Carolyn
29Rabban, Joseph
30Chen, Yunni-Yi
31Giri, Dilip
32Au, Alfred
33Hylton, Nola
atitleChemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
jtitleBreast Cancer Research and Treatment
stitleBreast Cancer Res Treat
risdate201204
volume132
issue3
spage1049
epage1062
issn0167-6806
eissn1573-7217
genrearticle
ristypeJOUR
abstractNeoadjuvant chemotherapy for breast cancer allows individual tumor response to be assessed depending on molecular subtype, and to judge the impact of response to therapy on recurrence-free survival (RFS). The multicenter I-SPY 1 TRIAL evaluated patients with ≥3 cm tumors by using early imaging and molecular signatures, with outcomes of pathologic complete response (pCR) and RFS. The current analysis was performed using data from patients who had molecular profiles and did not receive trastuzumab. The various molecular classifiers tested were highly correlated. Categorization of breast cancer by molecular signatures enhanced the ability of pCR to predict improvement in RFS compared to the population as a whole. In multivariate analysis, the molecular signatures that added to the ability of HR and HER2 receptors, clinical stage, and pCR in predicting RFS included 70-gene signature, wound healing signature, p53 mutation signature, and PAM50 risk of recurrence. The low risk signatures were associated with significantly better prognosis, and also identified additional patients with a good prognosis within the no pCR group, primarily in the hormone receptor positive, HER-2 negative subgroup. The I-SPY 1 population is enriched for tumors with a poor prognosis but is still heterogeneous in terms of rates of pCR and RFS. The ability of pCR to predict RFS is better by subset than it is for the whole group. Molecular markers improve prediction of RFS by identifying additional patients with excellent prognosis within the no pCR group.
copBoston
pubSpringer US
doi10.1007/s10549-011-1895-2
pages1049-1062
oafree_for_read
date2012-04